Factors affecting poor prognosis of COVID-19 in people living with human immunodeficiency virus: A systematic review and meta-analysis of co-infection
Abstract
Objectives: This study aims to assess the correlation between clinical features and mortality in human immunodeficiency virus (HIV)-infected individuals with COVID-19.
Methods: A systematic literature search was conducted for cohort, cross-sectional, and case series that reported co-infection with HIV and COVID-19 published from January to September 2020. Clinical features such as age, comorbidities, CD4+T lymphocyte counts, HIV RNA levels, and antiretroviral regimens were evaluated using meta-analyses and systematic reviews. Meta-analysis was performed using Stata 15.0 software.
Results: A total of 24 articles with 939 cases of HIV/COVID-19 co-infection were included in this study. The overall mortality rate was 10.3% (97/939). Older age and comorbidities including hypertension, diabetes, renal insufficiency, chronic obstructive pulmonary disease/asthma, and tumors were significantly associated with increased mortality (95% confidence interval 0.005–0.050, 0.042–2.294, 0.390–2.754, 0.513–2.848, 0.348–3.743, and 1.943–7.101, respectively, P = 0.021, 0.043, 0.012, 0.008,
0.022, and 0.005). There was no significant correlation between mortality and CD4+Tlymphocyte count <200/μL or >500/μL, HIV RNA level below the detection limit, or antiretroviral drugs (including tenofovir) (all P > 0.05). Improved HIV treatment,complex immune interactions, study population variability, and lack of direct SARSCoV-2 targeting by ART likely obscure the correlation between CD4+ counts or ARTand COVID-19 mortality in HIV patients.
Conclusion: HIV-infected individuals with COVID-19 have a similar prognosis to the general population. However, older age, comorbidities (hypertension and diabetesetc.), and lower CD4+ T-cell counts are associated with increased mortality. Mainstream anti-HIV drugs do not offer significant protection against COVID-19.
Keywords:
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).